檢索詞checkmate 032 gastric cancer; CTLA4 and Tumor Mutational Burden and gastric cancer; PD1 and Tumor Mutational Burden and gastric cancer; immune-checkpoint inhibition and Tumor Mutational Burden and gastric cancer.
CheckMate-032研究：Nivolumab和Nivolumab加上Ipilimumab在轉(zhuǎn)移性食管胃癌患者中的療效和安全性 (nih.gov)
A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer | Nature Reviews Clinical Oncology
結(jié)論：高TMB不能保證受益于免疫檢查點抑制（ICI）
Current status of immune checkpoint inhibitors for gastric cancer | SpringerLink
In addition, high tumor mutational burden (TMB) [73], T-cell inflamed gene profiling and interferon-γ gene signature [74], and circulating tumor DNA (ctDNA) [75] have been also reported as possible biomarkers predicting clinical outcomes of immunotherapy by ICI
Tumor Mutational Burden and Response Rate to PD-1 Inhibition (nih.gov)
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 - PubMed (nih.gov)
Ib / II期臨床試驗：高TMB可能是接受曲妥單抗單藥的AGC患者OS的預(yù)測指標妒挎。
腫瘤突變負擔作為胃癌PD-1抗體治療的新生物標志物 (nih.gov)
腫瘤突變負擔（TMB）最近已被描述為PD-1抗體治療的一種新的生物標志物。但是变抽，其在AGC中的預(yù)測作用尚未得到證實。在最近發(fā)表于《腫瘤學年鑒》上的一項研究中雏节，Wang等人嘶摊。[ 9 ]已將TMB鑒定為用托利帕單抗治療的難治性胃癌OS獲益的生物標志物曼追。作者通過使用全外顯子組測序（WES）測試了TMB栅受，發(fā)現(xiàn)TMB而非PD-L1與AGC的顯著生存獲益相關(guān)族铆。TMB-High組的OS明顯優(yōu)于TMB-Low組（14.6 vs 4.0個月岩四，HR = 0.48，P ?= 0.038）哥攘。這項研究是第一個將TMB識別為ICI在胃腸道（GI）癌癥中使用的預(yù)測性生物標志物剖煌。
Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer - PubMed (nih.gov)
110例使用抗PD-1 / PD-L1抗體，51例使用抗CTLA-4和PD-1 / PD-L1抗體: TMB與存活率提高相關(guān)逝淹，但是當排除MSI高的患者時未觀察到這種關(guān)聯(lián)耕姊。
